Next Article in Journal
18F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
Previous Article in Journal
Lung Ultrasound: A Diagnostic Leading Tool for SARS-CoV-2 Pneumonia: A Narrative Review
 
 
diagnostics-logo
Article Menu

Article Menu

Article
Peer-Review Record

Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

Diagnostics 2021, 11(12), 2380; https://doi.org/10.3390/diagnostics11122380
by Diego Santos García 1,*, Lucía Naya Ríos 1, Teresa de Deus Fonticoba 2, Carlos Cores Bartolomé 1, Lucía García Roca 1, Maria Feal Painceiras 1, Cristina Martínez Miró 1, Hector Canfield 2, Silvia Jesús 3,4, Miquel Aguilar 5, Pau Pastor 5, Marina Cosgaya 6, Juan García Caldentey 7, Nuria Caballol 8, Inés Legarda 9, Jorge Hernández Vara 10, Iria Cabo 11, Lydia López Manzanares 12, Isabel González Aramburu 4,13, María A. Ávila Rivera 14, Víctor Gómez Mayordomo 15, Víctor Nogueira 16, Víctor Puente 17, Julio Dotor 18, Carmen Borrué 19, Berta Solano Vila 20, María Álvarez Sauco 21, Lydia Vela 22, Sonia Escalante 23, Esther Cubo 24, Francisco Carrillo Padilla 25, Juan C. Martínez Castrillo 26, Pilar Sánchez Alonso 27, Maria G. Alonso Losada 28, Nuria López Ariztegui 29, Itziar Gastón 30, Jaime Kulisevsky 4,31, Marta Blázquez Estrada 32, Manuel Seijo 11, Javier Rúiz Martínez 33, Caridad Valero 34, Mónica Kurtis 35, Oriol de Fábregues 10, Jessica González Ardura 36, Ruben Alonso Redondo 37, Carlos Ordás 38, Luis M. López Díaz 39, Darrian McAfee 40, Pablo Martinez-Martin 4 and Pablo Mir 3,4,† on behalf of the COPPADIS Study Groupadd Show full author list remove Hide full author list
Reviewer 1:
Reviewer 2: Anonymous
Diagnostics 2021, 11(12), 2380; https://doi.org/10.3390/diagnostics11122380
Submission received: 23 November 2021 / Revised: 9 December 2021 / Accepted: 14 December 2021 / Published: 17 December 2021
(This article belongs to the Section Pathology and Molecular Diagnostics)

Round 1

Reviewer 1 Report

This is a very interesting study showing that diplopia is relatively frequent finding in Parkinson’s disease. Although it has been reported previously, neurologists may not be aware of this finding.

It is a bit of the a limitation that the patients did not have a neuro-ophthalmological examined and the mechanism of diplopia was not explored, however the authors address these points in the discussion.

The authors should mention that they did not exclude myasthenia gravis, microvascular disease, etc, as causes of diplopia.

Perhaps the authors overstate their findings, perhaps it is easier to ask about hallucinations directly rather than asking indirectly about diplopia, or there are more effective ways to determine severity in PD?

Author Response

Reviewer 1

This is a very interesting study showing that diplopia is relatively frequent finding in Parkinson’s disease. Although it has been reported previously, neurologists may not be aware of this finding.

It is a bit of the a limitation that the patients did not have a neuro-ophthalmological examined and the mechanism of diplopia was not explored, however the authors address these points in the discussion.

The authors should mention that they did not exclude myasthenia gravis, microvascular disease, etc, as causes of diplopia.

AUTHORS – Thank you very much for your comment. As you suggested, we clarified it and added in the text the next sentence: “Furthermore, it was not collected if the neurologists ruled out myasthenia gravis, microvascular disease or other causes of diplopia in their clinical practice”.

Perhaps the authors overstate their findings, perhaps it is easier to ask about hallucinations directly rather than asking indirectly about diplopia, or there are more effective ways to determine severity in PD?

AUTHORS – Thank you for your comment. Visual hallucinations (VH) were significantly more frequent in patients with diplopia than in those without diplopia (about 50% vs 10%). In patients with persisting diplopia the frequency was even up to 85% and to have VH was an independent factor in the binary model associated with diplopia (OR=2.264). However, we didn´t explore VH as a marker of severity disease in our cohort. Our conclusion is based on findings of this analysis and as it has been mentioned, to ask for diplopia is a simple question easy for patients to interpret. Although previous studies have reported an association between VH and longer duration and greater severity of illness (Barnes & Davis. J Neurol Neurosurg Psychiatry 2001;70:727-733), recent papers have observed that VH can be present in early PD patients and they are independently associated with dopamine agonist use, sleep quality and cognition, but not motor severity (Clegg et al. J Parkinsons Dis 2018;8:447-453; Zhu et al. J Neurol Sci 2017 Jan 15;372:471-476). Minor VH can be frequent even in the premotor phase of PD (Pagonabarraga et al. Mov Disord 2016;31:45-52) and their presence seem to be an early clinical marker of increased neurodegeneration linked to a cognitive non-motor PD phenotype (Bejr-Kasem H, et al. Eur J Neurol 2021;28:438-447). Based on our results and as a practical message, we concluded that to ask about the presence of diplopia when a PD patient is evaluated could be useful for screening disease severity.

Reviewer 2 Report

The article by Garcia DS et al titled as “Diplopia is frequent and associates with motor and non-motor severity in Parkinson ́s disease. Results from the COPPADIS cohort at 2-year follow-up” is a statistical analysis of ‘diplopia’ condition in PD patients from a multicenter Spanish cohort. Based on the COPPADIS cohort data, the authors reported a frequent diplopia condition in PD patients and also suggested the use of diplopia symptom as a clinical marker to score the disease condition/severity. The manuscript is well written, and the results have been interpreted appropriately. The present form can be accepted for publication.

Author Response

Reviewer 2

The article by Garcia DS et al titled as “Diplopia is frequent and associates with motor and non-motor severity in Parkinson ́s disease. Results from the COPPADIS cohort at 2-year follow-up” is a statistical analysis of ‘diplopia’ condition in PD patients from a multicenter Spanish cohort. Based on the COPPADIS cohort data, the authors reported a frequent diplopia condition in PD patients and also suggested the use of diplopia symptom as a clinical marker to score the disease condition/severity. The manuscript is well written, and the results have been interpreted appropriately. The present form can be accepted for publication.

AUTHORS – Thank you very much for your comment.

 

Author Response File: Author Response.doc

Back to TopTop